Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURVAST: Durvalumab in HIV-1 Patients With Advanced Solid Tumors
NCT03094286Phase 2Completed
- Sponsor
- Fundación GECP
- Start
- Apr 2017
- Primary completion
- Apr 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in solid tumor, sponsored by Fundación GECP. Started Apr 2017; status: completed.
02
Drugs
durvalumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03094286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03094286.